Dr. Benjamin Oakes, Ph.D. - CEO, Scribe Therapeutics - Engineering The Future Of Genetic Medicine episode artwork

EPISODE · Sep 11, 2024 · 46 MIN

Dr. Benjamin Oakes, Ph.D. - CEO, Scribe Therapeutics - Engineering The Future Of Genetic Medicine

from Progress, Potential, and Possibilities Podcast / Show · host Ira Pastor / Dr. Benjamin Oakes

Send us Fan MailDr. Benjamin L. Oakes, Ph.D., is Co-Founder, President, and Chief Executive Officer at Scribe Therapeutics ( https://www.scribetx.com/ ), a molecular engineering company focused on creating best-in-class CRISPR-based therapies that permanently treat the underlying cause of disease. Previously, as an Innovative Genomics Institute Entrepreneurial Fellow, Dr. Oakes focused on the holistic engineering of genome editing technologies to build novel genome editing molecules.Dr. Oakes has contributed to over 35 publications and patent applications across synthetic biology, molecular engineering, CRISPR, and zinc finger-based genetic modification. Dr. Oakes has been named to the MIT Technology Review 35 Innovators Under 35, San Francisco Business Times 40 Under 40, Endpoints 20 Under 40 in Biopharma, Business Insider 30 Under 40 Transforming Healthcare, and the Biocom Life Sciences Catalyst Awards. He received a Ph.D. in Molecular and Cellular Biology from the University of California, Berkeley, in 2017, where he worked in the Doudna Lab and Savage Lab developing CRISPR-Cas9 molecules with enhanced characteristics. Two such projects resulted in distinct versions of synthetic sensing systems that can modify nucleic acids only when triggered by external stimuli, and have found use in both research and pragmatically applied technologies.Prior to his Ph.D., Dr. Oakes received his B.A. in the fields of Philosophy and Neurobiology and worked as a researcher applying unbiased, combinatorial evolution methods to build tens of thousands of “version one” genome editing tools, providing an open source framework for scientists and medical professionals to modify the genome before the discovery of CRISPR technology.#BenjaminOakes #ScribeTherapeutics #MolecularEngineering #CRISPR #InnovativeGenomicsInstitute #JenniferDoudna #MolecularBiology #UniversityOfCalifornia #Berkeley #SyntheticBiology #ZincFingerNucleases #Optogenetics #EmmanuelleCharpentier  #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #STEM #Innovation #Technology #Science #ResearchSupport the show

Episode metadata supplied by the publisher feed · Published Sep 11, 2024

Embed this episode

Send us Fan Mail Dr. Benjamin L. Oakes, Ph.D., is Co-Founder, President, and Chief Executive Officer at Scribe Therapeutics ( https://www.scribetx.com/ ), a molecular engineering company focused on creating best-in-class CRISPR-based therapies that permanently treat the underlying cause of disease. Previously, as an Innovative Genomics Institute Entrepreneurial Fellow, Dr. Oakes focused on the holistic engineering of genome editing technologies to build novel genome editing molecules. Dr. Oa...

Distinct summary based on available episode metadata or transcript content.

NOW PLAYING

Dr. Benjamin Oakes, Ph.D. - CEO, Scribe Therapeutics - Engineering The Future Of Genetic Medicine

0:00 46:28

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Progress, Potential, and Possibilities Podcast / Show?

This episode is 46 minutes long.

When was this Progress, Potential, and Possibilities Podcast / Show episode published?

This episode was published on September 11, 2024.

Can I download this Progress, Potential, and Possibilities Podcast / Show episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!